Viroimmunotherapy in 9p21.3-deleted gliomas

Clicks: 8
ID: 333816
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #136 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract One of the most frequent genetic alterations in high-grade gliomas is the homozygous deletion of the 9p21.3 chromosomal region, affecting 20-50% of tumors. The 9p21.3 locus encodes key tumor suppressor genes (CDKN2A and CDKN2B), MTAP, and a cluster of type I interferon (IFN) genes. The loss of CDKN2A and CDKN2B deregulates the Rb and p53 pathways, driving uncontrolled proliferation and creating a replication-permissive state that oncolytic viruses can exploit. The simultaneous deletion of MTAP and type I IFN genes impairs innate immune surveillance, thereby enhancing viral replication but limiting the host’s capacity for adaptive immune priming. Hence, current evidence suggests that 9p21.3 deletions eliminate a proliferative block and promote immune evasion, contributing to tumorigenesis. Despite the high frequency of 9p21.3 loss in malignant gliomas, the extent to which this deletion affects the therapeutic efficacy of oncolytic viruses remains unclear. In this review, we discuss the potential of using 9p21.3 status as a biomarker of therapeutic response, the challenges of modeling 9p21.3 loss in preclinical glioma models, and future strategies to exploit oncolytic viral permissiveness while stimulating antitumor immunity in patients with high-grade gliomas and 9p21.3 loss.
Reference Key
openalex_W7223451671 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andres R. Lopez-Rivas, Andrew Gregg Gillard, Claudia Solbes-Godina Riera, Dong Ho Shin, Akhila Parthasarathy, Angelis M. Morales Rivera, Christopher A Alvarez-Breckenridge, Juan Fueyo-Margareto, Candelaria Gomez‐Manzano
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag270
URL
https://doi.org/10.1093/noajnl/vdag270
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.